NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $26.8 million in its fourth quarter.
The Newark, California-based company said it had a loss of 95 cents per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 82 cents per share.
The biopharmaceutical posted revenue of $75,000 in the period.
For the year, the company reported that its loss widened to $89.3 million, or $3.18 per share. Revenue was nearly unchanged at $300,000.
Revance shares have climbed roughly 2 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $21.10, a climb of 14 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RVNC at https://www.zacks.com/ap/RVNC
Keywords: Revance Therapeutics, Earnings Report